Excitotoxic ablation.
Guridi
J
J
Ramos
E
E
Linazasoro
G
G
Obeso
J A
JA
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016503:Drug Delivery Systems; D005917:Globus Pallidus / Q000187:drug effects*; D006801:Humans; D009474:Neurons / Q000187:drug effects / Q000473:pathology; D010300:Parkinson Disease / Q000188:drug therapy* / Q000473:pathology; D020734:Parkinsonian Disorders / Q000188:drug therapy*; D011323:Primates; D015203:Reproducibility of Results
D000978:Antiparkinson Agents; D015259:Dopamine Agents; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine